Real-World Evidence and Market Access.

Chloe: Welcome to the London School of Business and Administration podcast—where breakthrough ideas meet real-world impact. I'm Chloe, and today we're diving into Real-World Evidence and Market Access.—the one concept that quietly shapes everything from boardroom decisions to your daily workflow.

Rohan: And let me ask you this: Did you know that for every drug approved by regulators, only a fraction actually gets reimbursed by payers? It’s a brutal filter, isn’t it?

Priya: It is brutal, but it’s also where the real science meets the real economy. That gap between clinical trial data and real-world usage is where the magic—and the money—lives.

Chloe: Exactly. So, Priya, as our expert in this field, why is Real-World Evidence, or RWE, becoming such a non-negotiable pillar for market access right now?

Priya: It’s about trust, Chloe. Ten years ago, a pristine Phase III randomized controlled trial was the gold standard. But those trials are like driving a car on a test track. Perfect conditions, selected drivers, no traffic. Real-world evidence is driving that same car on a busy highway in the rain. Payers want to know: Does this work for *my* patients, with *their* comorbidities, in *our* healthcare system?

Rohan: I love that analogy. Because I remember early in my career, we had a biologic for rheumatoid arthritis. The trial data was gorgeous. Statistically significant, clean endpoints. We went into negotiations with a major European health technology assessment body, confident in our success.

Chloe: And?

Rohan: And we got stonewalled. They asked, "Great, but what happens when patients stop taking it because of injection site reactions? What happens when they have diabetes and kidney issues? Your trial excluded all of that." We had no answer because we hadn’t collected that data.

Priya: That is the classic pitfall. You optimize for regulatory approval, which is binary: safe and effective? Yes or no. But market access is about value: Is it worth the cost compared to the alternative, in the messy reality of practice?

Chloe: So, how do we bridge that gap? If I’m a market access professional listening, what’s the first step I should take?

Priya: You need to define your evidence generation strategy before you even finish your Phase III trials. You can’t wait until launch to figure out what data you need. You need to align with payers on the key uncertainties. What don’t they know? Is it long-term safety? Cost-effectiveness over five years? Patient quality of life?

Rohan: I learned this the hard way. We assumed that because our drug worked, the value was obvious. We didn’t engage with health economists early enough. By the time we realized we needed a comparative effectiveness study against the standard of care, we were two years behind schedule. That cost us market share we could never get back.

Chloe: That’s a sobering lesson. Two years is an eternity in pharma. So, Priya, what does a robust RWE framework look like? Is it just about collecting more data?

Priya: It’s not about volume; it’s about validity. You need high-quality observational data. Electronic health records, claims databases, patient registries. But you have to handle confounding factors carefully. Just because two patients took different drugs doesn’t mean the drug caused the difference in outcome. Maybe one patient was younger or had better access to care.

Rohan: Right. Causality versus correlation. I saw a case last quarter where a competitor used RWE to show their drug reduced hospitalizations. We dug into their methodology and found they hadn’t adjusted for socioeconomic status. Their patients were simply wealthier and had better support systems. When we presented that critique to the payer, it shifted the narrative entirely.

By the time we realized we needed a comparative effectiveness study against the standard of care, we were two years behind schedule.

Chloe: Wow. So RWE isn’t just a defensive tool; it’s an offensive one too. You can use it to challenge competitors or to reinforce your own value proposition.

Priya: Precisely. It’s about telling a richer story. Clinical trials tell you if a drug works. RWE tells you how it improves lives and saves money. For payers, that’s the language they speak.

Rohan: And it’s not just about cost savings. It’s about outcomes. I worked with a team recently that used patient-reported outcome measures from real-world settings. They showed that their therapy allowed patients to return to work faster. That economic benefit, combined with the clinical benefit, was the key to getting a favorable reimbursement decision.

Chloe: That’s powerful. It connects the medical to the personal and the economic. It’s holistic. So, for those of you building your career in market access, what’s the mindset shift needed here?

Priya: Move from being a data collector to being a story architect. Don’t just hand over a spreadsheet. Interpret the data. Contextualize it. Show the human impact behind the numbers. And collaborate early with epidemiologists, health economists, and data scientists.

Rohan: And be humble. Be ready to admit when your data doesn’t support your hypothesis. I’ve seen companies try to spin weak RWE, and payers smell that a mile away. Integrity is your currency. If you’re transparent about limitations and proactive about generating additional evidence to address them, you build trust.

Chloe: Trust. That’s the common thread. Trust from regulators, trust from payers, and ultimately, trust from patients.

Priya: Exactly. And as RWE methods improve, with better AI and machine learning techniques to clean and analyze complex data, that trust will only become more critical. We’re moving toward a world where real-world performance dictates market success, not just trial efficacy.

Rohan: It’s an exciting time to be in this space. The barriers are high, but the reward is delivering therapies that truly help people, in the way they live their lives.

Chloe: I love that vision. Delivering therapies that help people in the way they live their lives. That’s what it’s all about. Priya, Rohan, thank you so much for sharing your insights and stories.

Priya: Thank you, Chloe. It’s been a pleasure.

Rohan: Absolutely. Thanks for having us.

Chloe: If this resonated, share it with one person who needs to hear it—and hit subscribe so you never miss an episode that moves you forward.